MedTech Terms
    The authoritative reference
    All terms
    StandardsQuality SystemClinical EvidenceE6(R3)

    ICH E6(R3) Good Clinical Practice

    Revision 3 of the ICH Good Clinical Practice guideline, restructured around principles, modernized for risk-based and decentralized trials, finalized in 2023.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

    Definition

    ICH E6(R3) is the third major revision of the International Council for Harmonisation's Good Clinical Practice (GCP) guideline. Finalized in January 2025 (Step 4), it restructures GCP as a principles-based framework with two annexes: Annex 1 (interventional clinical trials) and Annex 2 (additional considerations for non-traditional designs including decentralized trials, real-world data integration, and pragmatic trials). R3 modernizes GCP for digital trials, sponsor-investigator collaboration, risk-based quality management, and the use of electronic systems, making explicit many expectations that were implicit in E6(R2) addendum.
    What the regulation says
    Finalized at ICH Step 4 in January 2025. FDA, EMA, MHRA, PMDA, Health Canada, NMPA, and other ICH members are in various stages of regional implementation. Many sponsors are transitioning protocols and SOPs to E6(R3) ahead of mandatory adoption dates.

    What this means in practice

    Although ICH GCP is primarily a drug guideline, FDA and ISO 14155 reference it for device trials and many medical device sponsors voluntarily follow it for global consistency. For sponsors running multinational device trials, alignment between ISO 14155:2020 and ICH E6(R3) governance models is essential. Regulators (FDA, EMA, MHRA, PMDA) all adopt ICH guidelines into national policy after Step 4 finalization.
    Common pitfalls
    • •Treating R3 as a minor update, the principles-based structure represents a meaningful shift in how GCP compliance is demonstrated.
    • •Maintaining E6(R2)-style SOPs after R3 adoption, many R2 prescriptive requirements no longer apply directly and must be re-evidenced against principles.
    • •Ignoring Annex 2, sponsors using decentralized or RWD-integrated designs need it.

    Primary references

    3 sources
    Link health: 2 verified 1 bot-blocked· last checked 2026-06-20
    ICH·1FDA·1AAMI·1
    1. 1
      ICH E6(R3) Guideline
      Verified
      ICHich.org
    2. 2
      FDA Implementation of ICH E6(R3)
      Bot-blocked
      FDAfda.gov
    3. 3
      AAMI Standards
      Verified
      AAMIaami.org

    Inline markers like [1] jump to the matching reference above.